Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Radiation Tolerance | 22 | 2021 | 508 | 4.680 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 31 | 2021 | 4913 | 2.850 |
Why?
|
Lung Neoplasms | 47 | 2022 | 12540 | 2.530 |
Why?
|
Radiation-Sensitizing Agents | 9 | 2021 | 385 | 2.530 |
Why?
|
Relative Biological Effectiveness | 7 | 2019 | 341 | 2.150 |
Why?
|
Radiosurgery | 13 | 2022 | 1349 | 2.070 |
Why?
|
Fanconi Anemia Complementation Group D2 Protein | 8 | 2015 | 151 | 1.980 |
Why?
|
DNA Repair | 19 | 2021 | 2034 | 1.730 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 7 | 2021 | 1634 | 1.490 |
Why?
|
Radiobiology | 5 | 2020 | 91 | 1.330 |
Why?
|
Radiation Injuries | 9 | 2020 | 1224 | 1.290 |
Why?
|
DNA Damage | 13 | 2021 | 2434 | 1.260 |
Why?
|
DNA Breaks, Double-Stranded | 11 | 2019 | 580 | 1.240 |
Why?
|
Rad51 Recombinase | 12 | 2016 | 184 | 1.200 |
Why?
|
Recombination, Genetic | 12 | 2013 | 1692 | 1.090 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 8 | 2020 | 1582 | 1.080 |
Why?
|
Tumor Suppressor Protein p53 | 10 | 2019 | 2946 | 1.040 |
Why?
|
Neoplasms | 22 | 2021 | 20528 | 1.020 |
Why?
|
Fanconi Anemia | 4 | 2016 | 322 | 0.900 |
Why?
|
Thoracic Wall | 3 | 2020 | 197 | 0.900 |
Why?
|
Radiotherapy | 10 | 2013 | 1614 | 0.830 |
Why?
|
Molecular Targeted Therapy | 7 | 2021 | 2824 | 0.820 |
Why?
|
Radiotherapy Dosage | 13 | 2021 | 2947 | 0.800 |
Why?
|
Phthalazines | 3 | 2018 | 357 | 0.770 |
Why?
|
Antineoplastic Agents | 16 | 2021 | 13626 | 0.760 |
Why?
|
Radiotherapy, Intensity-Modulated | 4 | 2016 | 791 | 0.750 |
Why?
|
BRCA1 Protein | 6 | 2015 | 1047 | 0.740 |
Why?
|
Uncertainty | 2 | 2013 | 659 | 0.640 |
Why?
|
Esophagus | 4 | 2021 | 1015 | 0.640 |
Why?
|
DNA Replication | 4 | 2021 | 1421 | 0.630 |
Why?
|
Fibroblasts | 6 | 2010 | 4228 | 0.620 |
Why?
|
Protein Kinase Inhibitors | 7 | 2020 | 5412 | 0.610 |
Why?
|
Head and Neck Neoplasms | 7 | 2015 | 2719 | 0.590 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2019 | 752 | 0.580 |
Why?
|
Cell Line, Tumor | 21 | 2021 | 16735 | 0.580 |
Why?
|
Recombinases | 1 | 2016 | 68 | 0.570 |
Why?
|
Gastroenterology | 1 | 2021 | 513 | 0.560 |
Why?
|
Osteopontin | 1 | 2017 | 352 | 0.540 |
Why?
|
Protons | 2 | 2021 | 1065 | 0.540 |
Why?
|
Fanconi Anemia Complementation Group A Protein | 2 | 2011 | 48 | 0.520 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2020 | 5198 | 0.510 |
Why?
|
Esophagitis | 1 | 2015 | 137 | 0.510 |
Why?
|
Reactive Oxygen Species | 2 | 2019 | 2099 | 0.490 |
Why?
|
Radiation Pneumonitis | 3 | 2016 | 98 | 0.470 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 725 | 0.470 |
Why?
|
Cell Survival | 9 | 2021 | 6035 | 0.460 |
Why?
|
Thoracic Neoplasms | 1 | 2015 | 265 | 0.460 |
Why?
|
Endonucleases | 1 | 2016 | 388 | 0.460 |
Why?
|
Piperazines | 3 | 2018 | 2524 | 0.430 |
Why?
|
ras Proteins | 2 | 2014 | 1102 | 0.420 |
Why?
|
Cisplatin | 4 | 2013 | 1654 | 0.420 |
Why?
|
Mutation | 23 | 2021 | 29290 | 0.400 |
Why?
|
DNA | 5 | 2021 | 7093 | 0.390 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2015 | 1834 | 0.380 |
Why?
|
Apoptosis | 6 | 2019 | 9971 | 0.370 |
Why?
|
Etoposide | 1 | 2011 | 627 | 0.370 |
Why?
|
Humans | 100 | 2023 | 715818 | 0.370 |
Why?
|
Fanconi Anemia Complementation Group Proteins | 1 | 2010 | 101 | 0.370 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2015 | 3994 | 0.350 |
Why?
|
Quinazolines | 3 | 2014 | 1408 | 0.350 |
Why?
|
Photons | 4 | 2019 | 608 | 0.340 |
Why?
|
Combined Modality Therapy | 13 | 2021 | 8890 | 0.340 |
Why?
|
Organoplatinum Compounds | 1 | 2010 | 429 | 0.330 |
Why?
|
Pneumonectomy | 1 | 2015 | 1076 | 0.320 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2015 | 3551 | 0.310 |
Why?
|
Guidelines as Topic | 1 | 2013 | 1418 | 0.290 |
Why?
|
DNA-Binding Proteins | 10 | 2016 | 9730 | 0.290 |
Why?
|
G1 Phase | 2 | 2015 | 419 | 0.290 |
Why?
|
Chromosome Breakage | 1 | 2006 | 172 | 0.290 |
Why?
|
Cell Cycle Proteins | 5 | 2011 | 3484 | 0.290 |
Why?
|
Cobalt Radioisotopes | 2 | 2016 | 79 | 0.290 |
Why?
|
Small Cell Lung Carcinoma | 3 | 2016 | 354 | 0.280 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2018 | 2077 | 0.280 |
Why?
|
Signal Transduction | 7 | 2018 | 23729 | 0.280 |
Why?
|
Organs at Risk | 4 | 2019 | 341 | 0.270 |
Why?
|
Neoplasm Staging | 7 | 2019 | 11145 | 0.260 |
Why?
|
Medical Oncology | 3 | 2023 | 2118 | 0.260 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4647 | 0.260 |
Why?
|
Cell Proliferation | 6 | 2021 | 10615 | 0.250 |
Why?
|
Endodeoxyribonucleases | 2 | 2016 | 167 | 0.240 |
Why?
|
Mice, Nude | 3 | 2019 | 3801 | 0.230 |
Why?
|
Pharmaceutical Preparations | 2 | 2021 | 1042 | 0.230 |
Why?
|
Chromatin | 1 | 2014 | 2686 | 0.230 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3897 | 0.220 |
Why?
|
Radiation Dosage | 5 | 2017 | 2041 | 0.220 |
Why?
|
Radiation Oncology | 2 | 2018 | 510 | 0.220 |
Why?
|
Animals | 29 | 2021 | 169404 | 0.220 |
Why?
|
Radiation, Ionizing | 4 | 2011 | 275 | 0.210 |
Why?
|
Mitomycin | 2 | 2013 | 249 | 0.210 |
Why?
|
Mice | 18 | 2021 | 80373 | 0.210 |
Why?
|
Parental Leave | 1 | 2021 | 81 | 0.200 |
Why?
|
Evidence-Based Medicine | 1 | 2013 | 3683 | 0.200 |
Why?
|
Breast | 1 | 2009 | 1819 | 0.200 |
Why?
|
Transplantation, Heterologous | 2 | 2019 | 2425 | 0.200 |
Why?
|
Cell Line | 9 | 2015 | 16575 | 0.190 |
Why?
|
Melanoma, Experimental | 1 | 2003 | 556 | 0.190 |
Why?
|
Neoplastic Stem Cells | 3 | 2017 | 1373 | 0.190 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9549 | 0.190 |
Why?
|
Neoplasm Recurrence, Local | 8 | 2020 | 8896 | 0.190 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2022 | 152 | 0.190 |
Why?
|
Alginates | 1 | 2021 | 245 | 0.180 |
Why?
|
Cranial Irradiation | 2 | 2020 | 441 | 0.180 |
Why?
|
Aged, 80 and over | 18 | 2021 | 58326 | 0.180 |
Why?
|
Clinical Trials as Topic | 7 | 2021 | 7960 | 0.170 |
Why?
|
Histones | 2 | 2011 | 2551 | 0.170 |
Why?
|
S Phase | 1 | 2000 | 434 | 0.170 |
Why?
|
Policy | 1 | 2021 | 375 | 0.170 |
Why?
|
Female | 41 | 2023 | 377229 | 0.170 |
Why?
|
Bicarbonates | 1 | 2019 | 311 | 0.170 |
Why?
|
rac1 GTP-Binding Protein | 1 | 2019 | 248 | 0.170 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2020 | 262 | 0.160 |
Why?
|
Genes, p53 | 1 | 2000 | 764 | 0.160 |
Why?
|
Oxygen | 1 | 2009 | 4162 | 0.160 |
Why?
|
Physicians, Women | 1 | 2023 | 473 | 0.150 |
Why?
|
Gene Conversion | 3 | 2008 | 68 | 0.150 |
Why?
|
Lung | 6 | 2019 | 9739 | 0.150 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 38 | 0.150 |
Why?
|
Carcinoma, Medullary | 1 | 1997 | 124 | 0.150 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2019 | 263 | 0.150 |
Why?
|
Oxidative Stress | 1 | 2008 | 3129 | 0.150 |
Why?
|
Tumor Burden | 4 | 2017 | 1900 | 0.150 |
Why?
|
Aged | 24 | 2022 | 162468 | 0.140 |
Why?
|
Research Report | 1 | 2019 | 358 | 0.140 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 548 | 0.140 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 657 | 0.130 |
Why?
|
Brain Neoplasms | 4 | 2020 | 8805 | 0.130 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2015 | 11236 | 0.130 |
Why?
|
Kaplan-Meier Estimate | 8 | 2020 | 6730 | 0.130 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2018 | 420 | 0.130 |
Why?
|
Middle Aged | 25 | 2021 | 214666 | 0.130 |
Why?
|
Male | 30 | 2023 | 350352 | 0.130 |
Why?
|
Cell Cycle | 3 | 2018 | 2991 | 0.130 |
Why?
|
Rhabdomyosarcoma | 1 | 1997 | 380 | 0.130 |
Why?
|
Linear Energy Transfer | 1 | 2015 | 169 | 0.130 |
Why?
|
History, 20th Century | 5 | 2006 | 2823 | 0.120 |
Why?
|
Cell Transformation, Neoplastic | 2 | 2004 | 2985 | 0.120 |
Why?
|
Protein Kinase C-alpha | 1 | 2014 | 117 | 0.120 |
Why?
|
Neoplasm Metastasis | 4 | 2020 | 5074 | 0.120 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 122 | 0.120 |
Why?
|
Fellowships and Scholarships | 1 | 2021 | 992 | 0.120 |
Why?
|
Cell Division | 2 | 2000 | 4697 | 0.120 |
Why?
|
Thymus Neoplasms | 1 | 2015 | 254 | 0.120 |
Why?
|
Flow Cytometry | 2 | 2016 | 6093 | 0.120 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2019 | 3633 | 0.120 |
Why?
|
Biopsy | 2 | 2019 | 6737 | 0.110 |
Why?
|
Pyrazines | 1 | 2019 | 1246 | 0.110 |
Why?
|
Congresses as Topic | 1 | 2017 | 775 | 0.110 |
Why?
|
Meta-Analysis as Topic | 1 | 1998 | 1373 | 0.110 |
Why?
|
Carcinoma, Lobular | 1 | 1997 | 495 | 0.110 |
Why?
|
Exodeoxyribonucleases | 1 | 2013 | 182 | 0.110 |
Why?
|
Radiography | 2 | 2015 | 6980 | 0.110 |
Why?
|
Plasmids | 4 | 2004 | 2459 | 0.110 |
Why?
|
RNA Interference | 2 | 2011 | 2985 | 0.110 |
Why?
|
Poly(ADP-ribose) Polymerases | 1 | 2013 | 425 | 0.110 |
Why?
|
NIH 3T3 Cells | 1 | 2013 | 691 | 0.110 |
Why?
|
Thymidine | 1 | 2011 | 342 | 0.110 |
Why?
|
Topoisomerase II Inhibitors | 1 | 2011 | 84 | 0.100 |
Why?
|
Cells, Cultured | 5 | 2011 | 19905 | 0.100 |
Why?
|
DNA Topoisomerases, Type II | 1 | 2011 | 116 | 0.100 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 4586 | 0.100 |
Why?
|
Antigens, Nuclear | 2 | 2008 | 203 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2019 | 1121 | 0.100 |
Why?
|
Fluorescent Antibody Technique | 2 | 2015 | 2647 | 0.100 |
Why?
|
Fanconi Anemia Complementation Group C Protein | 1 | 2010 | 21 | 0.100 |
Why?
|
Models, Theoretical | 2 | 2020 | 3579 | 0.100 |
Why?
|
Lymphocytes | 1 | 2019 | 2737 | 0.100 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2016 | 1402 | 0.100 |
Why?
|
Germany | 3 | 1998 | 836 | 0.100 |
Why?
|
Cell Hypoxia | 1 | 2013 | 683 | 0.100 |
Why?
|
Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2011 | 281 | 0.100 |
Why?
|
Oncogenes | 1 | 2016 | 1246 | 0.100 |
Why?
|
Treatment Outcome | 13 | 2020 | 62040 | 0.100 |
Why?
|
Models, Biological | 5 | 2021 | 9809 | 0.100 |
Why?
|
Reproducibility of Results | 3 | 2021 | 19537 | 0.090 |
Why?
|
Exonucleases | 1 | 2009 | 44 | 0.090 |
Why?
|
History, 19th Century | 2 | 2006 | 742 | 0.090 |
Why?
|
Genes, erbB-1 | 1 | 2010 | 170 | 0.090 |
Why?
|
Breast Neoplasms | 5 | 2009 | 20062 | 0.090 |
Why?
|
Immunoenzyme Techniques | 1 | 2013 | 1833 | 0.090 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 1997 | 1103 | 0.090 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2013 | 675 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2207 | 0.090 |
Why?
|
Frozen Sections | 1 | 2009 | 164 | 0.090 |
Why?
|
Benzimidazoles | 1 | 2014 | 877 | 0.090 |
Why?
|
Practice Guidelines as Topic | 2 | 2019 | 7446 | 0.090 |
Why?
|
Retrospective Studies | 10 | 2022 | 72473 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2018 | 1571 | 0.080 |
Why?
|
Cell Line, Transformed | 1 | 2010 | 976 | 0.080 |
Why?
|
Transcriptional Activation | 3 | 2011 | 1839 | 0.080 |
Why?
|
Cross-Linking Reagents | 1 | 2011 | 724 | 0.080 |
Why?
|
3T3 Cells | 2 | 2000 | 1121 | 0.080 |
Why?
|
Reference Values | 1 | 2015 | 5050 | 0.080 |
Why?
|
Hippocampus | 1 | 2020 | 3628 | 0.080 |
Why?
|
Intracellular Signaling Peptides and Proteins | 2 | 2015 | 2977 | 0.080 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2014 | 1633 | 0.070 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 2 | 2008 | 177 | 0.070 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2011 | 714 | 0.070 |
Why?
|
Transfection | 2 | 2013 | 6089 | 0.070 |
Why?
|
Respiration | 1 | 2013 | 1670 | 0.070 |
Why?
|
Tumor Cells, Cultured | 2 | 2013 | 6482 | 0.070 |
Why?
|
Prospective Studies | 5 | 2022 | 51317 | 0.070 |
Why?
|
France | 2 | 1998 | 496 | 0.070 |
Why?
|
Soft Tissue Neoplasms | 1 | 1995 | 1356 | 0.070 |
Why?
|
Neutrophils | 1 | 2019 | 3800 | 0.070 |
Why?
|
Movement | 1 | 2013 | 1473 | 0.070 |
Why?
|
Sarcoma | 1 | 1997 | 1879 | 0.070 |
Why?
|
Linear Models | 1 | 2016 | 5984 | 0.070 |
Why?
|
Microscopy, Fluorescence | 1 | 2013 | 2807 | 0.070 |
Why?
|
Sequence Homology, Nucleic Acid | 1 | 2006 | 1119 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 11201 | 0.070 |
Why?
|
Crossing Over, Genetic | 2 | 2001 | 100 | 0.070 |
Why?
|
Manure | 1 | 2004 | 7 | 0.060 |
Why?
|
Mitochondria | 1 | 2018 | 3613 | 0.060 |
Why?
|
Genotype | 3 | 2017 | 12919 | 0.060 |
Why?
|
Health Services Accessibility | 1 | 2021 | 5038 | 0.060 |
Why?
|
Drug Resistance | 1 | 2010 | 1609 | 0.060 |
Why?
|
Sphingomyelin Phosphodiesterase | 1 | 2003 | 94 | 0.060 |
Why?
|
Ubiquitin | 1 | 2008 | 827 | 0.060 |
Why?
|
Base Sequence | 4 | 2015 | 13179 | 0.060 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2011 | 9596 | 0.060 |
Why?
|
Ammonia | 1 | 2004 | 238 | 0.060 |
Why?
|
Tumor Microenvironment | 3 | 2019 | 3054 | 0.060 |
Why?
|
Spinal Cord | 1 | 2011 | 1808 | 0.060 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2006 | 1778 | 0.060 |
Why?
|
Lymph Nodes | 1 | 2014 | 3424 | 0.060 |
Why?
|
Immunotherapy | 1 | 2018 | 4095 | 0.060 |
Why?
|
Bioreactors | 1 | 2004 | 237 | 0.060 |
Why?
|
Catheter Ablation | 2 | 2014 | 2558 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2013 | 2322 | 0.060 |
Why?
|
Biomedical Research | 1 | 2018 | 3268 | 0.060 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2008 | 1312 | 0.060 |
Why?
|
Liver Neoplasms | 1 | 2017 | 4102 | 0.050 |
Why?
|
Homeodomain Proteins | 1 | 2011 | 2442 | 0.050 |
Why?
|
Calcium Chloride | 1 | 2021 | 81 | 0.050 |
Why?
|
DNA Mutational Analysis | 2 | 2010 | 4296 | 0.050 |
Why?
|
Genomics | 1 | 2017 | 5342 | 0.050 |
Why?
|
Monte Carlo Method | 2 | 2019 | 1306 | 0.050 |
Why?
|
Follow-Up Studies | 4 | 2017 | 39305 | 0.050 |
Why?
|
Survival Analysis | 3 | 2020 | 10503 | 0.050 |
Why?
|
Treatment Failure | 2 | 2017 | 2677 | 0.050 |
Why?
|
Postoperative Care | 2 | 1997 | 1510 | 0.050 |
Why?
|
History, 21st Century | 1 | 2006 | 1566 | 0.050 |
Why?
|
Inflammation | 1 | 2019 | 10082 | 0.050 |
Why?
|
Genes, BRCA2 | 1 | 2002 | 592 | 0.040 |
Why?
|
Cell Growth Processes | 1 | 2019 | 403 | 0.040 |
Why?
|
Ohio | 1 | 2019 | 350 | 0.040 |
Why?
|
Rats | 3 | 2000 | 24852 | 0.040 |
Why?
|
Societies, Medical | 2 | 2023 | 3754 | 0.040 |
Why?
|
Genomic Instability | 2 | 2015 | 689 | 0.040 |
Why?
|
Codon | 1 | 2000 | 609 | 0.040 |
Why?
|
Cultural Diversity | 1 | 2021 | 347 | 0.040 |
Why?
|
Mice, SCID | 1 | 2003 | 2787 | 0.040 |
Why?
|
Neoplasms, Experimental | 1 | 2003 | 1323 | 0.040 |
Why?
|
Trans-Activators | 1 | 2008 | 3047 | 0.040 |
Why?
|
Time Factors | 5 | 2020 | 40887 | 0.040 |
Why?
|
Triazines | 1 | 2020 | 311 | 0.040 |
Why?
|
Standard of Care | 1 | 2021 | 522 | 0.040 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 2019 | 914 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 439 | 0.040 |
Why?
|
Alanine | 1 | 2000 | 586 | 0.040 |
Why?
|
Adenocarcinoma | 1 | 2015 | 6324 | 0.040 |
Why?
|
Disease Progression | 3 | 2020 | 13215 | 0.040 |
Why?
|
Prognosis | 4 | 2019 | 29007 | 0.040 |
Why?
|
Gene Amplification | 1 | 2001 | 1078 | 0.040 |
Why?
|
Analysis of Variance | 2 | 2016 | 6502 | 0.040 |
Why?
|
Early Detection of Cancer | 2 | 2022 | 2939 | 0.040 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18197 | 0.040 |
Why?
|
National Cancer Institute (U.S.) | 1 | 2017 | 260 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 2 | 2008 | 1966 | 0.040 |
Why?
|
Switzerland | 1 | 1996 | 259 | 0.040 |
Why?
|
Drug Combinations | 1 | 2021 | 1928 | 0.040 |
Why?
|
Survival Rate | 3 | 2019 | 13213 | 0.040 |
Why?
|
Up-Regulation | 2 | 2008 | 4312 | 0.040 |
Why?
|
DNA Primers | 2 | 2015 | 2979 | 0.040 |
Why?
|
Disease-Free Survival | 2 | 2016 | 7015 | 0.040 |
Why?
|
Radiation Injuries, Experimental | 1 | 1996 | 96 | 0.040 |
Why?
|
Nuclear Proteins | 2 | 2008 | 5947 | 0.030 |
Why?
|
Embryo, Mammalian | 1 | 2001 | 1749 | 0.030 |
Why?
|
Quality of Life | 1 | 2016 | 11722 | 0.030 |
Why?
|
Comet Assay | 1 | 2015 | 79 | 0.030 |
Why?
|
Molecular Sequence Data | 2 | 2006 | 18591 | 0.030 |
Why?
|
Models, Genetic | 2 | 2002 | 3516 | 0.030 |
Why?
|
Adult | 10 | 2017 | 212279 | 0.030 |
Why?
|
Benzamides | 1 | 2020 | 1390 | 0.030 |
Why?
|
Proportional Hazards Models | 3 | 2016 | 12460 | 0.030 |
Why?
|
Imidazoles | 1 | 2020 | 1249 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 3 | 2022 | 20357 | 0.030 |
Why?
|
Fluorouracil | 1 | 1997 | 1610 | 0.030 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2011 | 15603 | 0.030 |
Why?
|
Cohort Studies | 3 | 2021 | 40032 | 0.030 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1987 | 0.030 |
Why?
|
Europe | 1 | 1998 | 3343 | 0.030 |
Why?
|
Mice, Inbred BALB C | 1 | 2000 | 6641 | 0.020 |
Why?
|
Methotrexate | 1 | 1997 | 1725 | 0.020 |
Why?
|
Genes, Reporter | 2 | 2008 | 1603 | 0.020 |
Why?
|
United States | 2 | 2017 | 67910 | 0.020 |
Why?
|
HeLa Cells | 1 | 2016 | 3213 | 0.020 |
Why?
|
Rabbits | 1 | 1996 | 5060 | 0.020 |
Why?
|
Consensus | 1 | 2018 | 2744 | 0.020 |
Why?
|
Menopause | 1 | 1997 | 1535 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 1997 | 2968 | 0.020 |
Why?
|
Calcium | 1 | 2022 | 5800 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 2 | 2018 | 8571 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8240 | 0.020 |
Why?
|
Neoplasm Proteins | 1 | 2001 | 3741 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2000 | 8542 | 0.020 |
Why?
|
Gene Expression | 1 | 2001 | 7954 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 611 | 0.020 |
Why?
|
Research | 1 | 1996 | 2016 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 2 | 2011 | 2883 | 0.020 |
Why?
|
Preoperative Care | 1 | 1997 | 2345 | 0.020 |
Why?
|
BRCA2 Protein | 2 | 2002 | 704 | 0.020 |
Why?
|
Peptide Fragments | 1 | 2000 | 5111 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 4893 | 0.020 |
Why?
|
DNA, Single-Stranded | 1 | 2008 | 334 | 0.020 |
Why?
|
Methylation | 1 | 2009 | 1097 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 1997 | 2729 | 0.020 |
Why?
|
Massachusetts | 1 | 2019 | 8743 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5378 | 0.020 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2011 | 622 | 0.020 |
Why?
|
Cricetulus | 1 | 2008 | 853 | 0.020 |
Why?
|
Ovarian Neoplasms | 1 | 2002 | 4751 | 0.020 |
Why?
|
Binding Sites | 2 | 2006 | 6213 | 0.020 |
Why?
|
Diagnostic Tests, Routine | 1 | 2011 | 790 | 0.020 |
Why?
|
CHO Cells | 1 | 2008 | 1437 | 0.020 |
Why?
|
Enzyme Activation | 1 | 2011 | 3818 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2019 | 11689 | 0.020 |
Why?
|
Replication Protein A | 1 | 2004 | 65 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2009 | 1550 | 0.020 |
Why?
|
Research Design | 1 | 2020 | 5902 | 0.020 |
Why?
|
Fertilizers | 1 | 2004 | 17 | 0.020 |
Why?
|
Waste Disposal, Fluid | 1 | 2004 | 31 | 0.020 |
Why?
|
Cricetinae | 1 | 2008 | 2589 | 0.020 |
Why?
|
Radiology | 1 | 1997 | 1949 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2011 | 1974 | 0.020 |
Why?
|
Incidence | 1 | 2022 | 20733 | 0.020 |
Why?
|
Phosphorylation | 2 | 2006 | 8657 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9504 | 0.010 |
Why?
|
Glioma | 1 | 1997 | 3302 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2011 | 2995 | 0.010 |
Why?
|
Transcription Factors | 1 | 2001 | 11953 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2021 | 23437 | 0.010 |
Why?
|
Kinetics | 1 | 2008 | 6654 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2006 | 1773 | 0.010 |
Why?
|
Serine | 1 | 2004 | 827 | 0.010 |
Why?
|
Gene Deletion | 1 | 2008 | 2824 | 0.010 |
Why?
|
Chloramphenicol O-Acetyltransferase | 1 | 1999 | 228 | 0.010 |
Why?
|
Comorbidity | 1 | 2014 | 10435 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9799 | 0.010 |
Why?
|
Algorithms | 1 | 2019 | 13758 | 0.010 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2008 | 1842 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2004 | 2597 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2008 | 3574 | 0.010 |
Why?
|
Neurosurgical Procedures | 1 | 2010 | 2034 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2017 | 11940 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2008 | 2973 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2011 | 12483 | 0.010 |
Why?
|
Young Adult | 2 | 2014 | 56228 | 0.010 |
Why?
|
Swine | 1 | 2004 | 5802 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9558 | 0.010 |
Why?
|
Air Pollutants | 1 | 2004 | 2632 | 0.010 |
Why?
|
Risk Factors | 1 | 2011 | 70879 | 0.000 |
Why?
|
Gene Expression Regulation | 1 | 2002 | 12305 | 0.000 |
Why?
|